Facioscapulohumeral Muscular Dystrophy

Facioscapulohumeral muscular dystrophy (FSHD or FSH) is characterised by muscle weakness that affects the muscles of the face, shoulders and arms and appears in adolescence or adulthood. This disease is due to a change in the structure of a small region of chromosome 4, the D4Z4 region.


Clinical trials ongoing at the Institute:

  • Resolve-RD France = Resolve Expansion: CTRN FSHD France – Prospective 18 months MRI Study
  • PROGRESS FSHD: Remote assessment and artificial intelligence analysis to validate new outcome measures, biomarkers and therapeutic targets for FacioScapuloHumeral muscular dystrophy
  • ReSOLVE FSHD International: Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
  • 1821-FSH-301: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Subjects with Facioscapulohumeral Muscular Dystrophy (FSHD)



Resolve France Expansion



ReSOLVE FSHD International




Intervention FSH-301
Principal investigator
Teresinha Evangelista Teresinha Evangelista Guillaume Bassez Teresinha Evangelista
Sponsor CHU of Nice CHU of Nice CHU of Nice Fulcrum Therapeutics
Study status
Active In preparation Active Beginning soon
Recruitment status Ongoing Beginning soon Completed Beginning soon
Population Adult Adult Adult Adult
  + infos on clinicaltrials.gov + infos on clinicaltrials.gov


Contact : essais-adultes@institut-myologie.org